Actavis Elizabeth LLC

Company overview. Actavis Elizabeth LLC is a Delaware-organized limited liability company whose principal facility is a pharmaceutical manufacturing plant at 200 Elmora Avenue, Elizabeth, New Jersey — licensed as a drug manufacturer there since at least 1990. It is an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc., part of Teva Pharmaceutical Industries Ltd (NYSE/TSX: TEVA), the Israeli-headquartered generics company with roughly 37,000 employees and about $16.5 billion in 2024 revenue per its 10-K. Actavis Elizabeth came under Teva in the 2016 purchase of the Actavis generics business (formerly Watson Pharmaceuticals) from Allergan. No reliable standalone revenue or headcount figures for the subsidiary are published; directory estimates (2 employees, ~$260K revenue) are inconsistent with a licensed manufacturing site and should not be relied upon.

Products / operations. Actavis Elizabeth is an operating company, not a patent-assertion entity. It manufactures and markets generic oral solid-dose pharmaceuticals under FDA abbreviated new drug applications (ANDAs); approved products include clonidine HCl extended-release tablets, gabapentin capsules, lisdexamfetamine dimesylate capsules, and alprazolam tablets (per FDA and state licensing records). Its member is Actavis, LLC (Parsippany, NJ), and it does business as "Actavis US" within Actavis Pharma, Inc.

Patent-litigation posture. The tracked database shows a single appearance, as petitioner (plaintiff): Actavis Elizabeth LLC et al. v. Novartis AG (PTAB, filed 2017-08-15), an inter partes review of U.S. Patent No. 9,187,405 covering S1P receptor modulators for relapsing-remitting multiple sclerosis (fingolimod/Gilenya). Because this is a PTAB proceeding, plaintiff-friendly venue analysis (e.g., Eastern District of Texas) does not apply. The plaintiff-side count reflects a generic company challenging a brand-owner patent, not an NPE asserting purchased patents.

Notable context. The IPR (IPR2017-01946) was joined with IPR2017-00854, reached a final written decision in 2018, and Actavis Elizabeth and co-petitioner Teva Pharmaceuticals USA appealed to the Federal Circuit (No. 18-2260, closed March 2019). The petition supported Teva's generic fingolimod ANDA effort within the broader Novartis–Teva Hatch-Waxman dispute over Gilenya. In practice the entity appears in Hatch-Waxman ANDA litigation — often as a defendant in district court — although only the PTAB matter appears in the tracked data. Sources: Teva 10-K, Unified Patents PTAB portal, FDA records, and state corporate filings.